Effects of Asparagus Officinalis on Immune System Mediated Eae Model of Multiple Sclerosis Publisher



Aliomrani M^{1, 3} ; Rezaei M¹ ; Dinani MS² ; Mesripour A¹ Show Affiliations
Source: Toxicology Research Published:2022

Abstract

Background: About 5 to 10 percent of the population in developed countries are affected by autoimmune diseases. One of the most important autoimmune disease with high prevalence rate is Multiple sclerosis in which there is currently no definitive cure for it, and most medications such as interferons are used only to limit the disease. The present study aims to investigate the effect of using Asparagus Officinalis fractions in an immune system mediated model of multiple sclerosis. Material and Methods: Fractionation was performed by maceration using n-hexane, chloroform, chloroform-methanol (9: 1), n-Butanol and methanol solvents from aerial parts of Asparagus Officinalis. Thin layer chromatography, NMR and phenolic component measurement were done and two fractions were selected for checking in MS induced in vivo model. Results: It was observed that chloroform-methanolic and N-Butanol fractions had higher content of saponin in comparison of other extracts. Also, it was showed that the methanolic and n-Butanol extracts contains the highestportion of glycosylic steroid saponins in comparison to other fractions. Regarding experimental autoimmune encephalomyelitis (EAE) score, Butanolic and methanolic fractions with doses higher that 100mg/kg showed a potent supportive effects as long as locomotor activity protection even in lower dose in comparison to phosphate buffered saline (PBS) group. Conclusion: Considering the proved different effects of saponin compounds on the immune system we observed that those fractions altered the circulatory peripheral blood cells and also remit the clinical signs after EAE induction along with enhanced myelin sheath content in the median region of corpus callusom. It could be inferred that this fractions are promising candidates for further investigation as dose-dependent immune system regulating compounds in multiple sclerosis patients. © 2022 The Author(s). Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.